Hyperlipidemia Drugs Market Surpassed USD 20.7 Bn in 2021, impelled by increasing investment for healthcare infrastructure | insightSLICE
The global Hyperlipidemia Drugs market size was estimated to be US$ 20.7 billion in 2021 and is expected grow at a CAGR of 2.7% between 2023 to 2032.
The two most common lipid subtypes found in the blood are triglycerides and cholesterol, and an unusually high increase in either of these is called hyperlipidemia. Hyperlipidemia is therefore a medical term in which a patient has unusually high blood lipid levels.
High triglycerides are formed in your body when your cells store nutrients that your body does not require for energy production. Genetic factors are responsible for primary hyperlipidemia conditions, whereas biological and lifestyle influences cause secondary hyperlipidemia. For many years, statins have been the first-line treatment for hyperlipidemia.
Access the sample report: https://www.insightslice.com/request-sample/1294
Global Hyperlipidemia Drugs Market Key Segments:
- PCSK9 Inhibitors
- Bile Acid Sequestrants
- Cholesterol Absorption Inhibitors
- Fibric Acid Derivatives
By Route of Administration
- Specialty Clinics
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- North America
- United States
- Rest of North America
- United Kingdom
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of the Middle East & Africa
- South America
- Rest of South America
It is quite common, particularly in wealthier nations, and the disorder is spreading to other countries as well. The major reasons for this condition include unhealthy lifestyle, excessive alcohol consumption, and changes in the diet trend. Consumption of red meat, fried and processed meals, sweets, and high-fat foods raises cholesterol in the blood and is a main cause of hyperlipidemia worldwide.
Hyperlipidemia can lead to myocardial infarction, vascular disorders, atherosclerosis, hypertension, obesity, depression, and coronary heart disease. Hyperlipidemia raises the likelihood of coronary artery disease (CAD), which is caused by blocked arteries, significantly.
Hyperlipidemia, however, is relatively curable with medicines that either accelerate the clearance of excess triglycerides from the body or inhibit lipoprotein formation. These medications also lower harmful bad cholesterol, which is essential for minimizing the danger of a heart attack or stroke. As a result of increasing obesity and sedentary lifestyles across the world, the hyperlipidemia therapy market is expected to develop.
The key players of the Global Hyperlipidemia Drugs Market are:
Companies with a large presence in the global hyperlipidemia drugs market are AstraZeneca, Amgen Inc, Bristol-Myers Squibb Company, Alnylam Pharmaceuticals Inc, Daiichi Sankyo Company Limited, Esperion Therapeutics Inc, Eli Lilly and Company, Hoffmann-La Roche Ltd, Mylan N.V., Teva Pharmaceutical Industries Ltd, Sanofi, Pfizer Inc, GlaxoSmithKline PLC, Novartis AG, Johnson & Johnson Private Limited, Sun Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc, Reddy’s Laboratories Ltd, Formac Pharmaceuticals N.V. and others.
Read more about the report inclusions: https://www.insightslice.com/hyperlipidemia-drugs-market
Driving factors for the growth of Global Hyperlipidemia Drugs Market
World Health Organization (WHO), reports that the geriatric population across the world is expected to increase to nearly 2 billion by 2050. As a person’s age increases, the occurrence of cholesterol and cardiovascular disorders also increases. This is because in old age, cellular and anatomical functions are hampered, causing low clearance of lipids from the body.
Also, the lifetime aggregation of lipids (atherosclerosis) and arterial stiffness can result in increased susceptibility to CVD. These factors will propel the prescription of hyperlipidemia drugs, and therefore, the rising geriatric population will help in the growth of the hyperlipidemia drug market.
The growing need for hyperlipidemia medications and treatments to treat high levels of lipids induced by the aforementioned factors has boosted the demand for hyperlipidemia therapies and treatments.
Furthermore, the demand for hyperlipidemia medicines will grow in the next few years due to an increase in cardiovascular diseases associated with chronic hypercholesterolemia, which would encourage the expansion of the global hyperlipidemia drug market.
Due to an increasing demand for new drugs after the COVID-19 global pandemic and associated comorbidities observed in cardiovascular diseases, there is an increase in funding for hyperlipidemia medical research, which will also enable the growth of the hyperlipidemia drug market.
Increased awareness among patients regarding hyperlipidemia and an increase in public and private healthcare expenditure has further bolstered the hyperlipidemia drug market growth. Furthermore, the modernisation of the healthcare sector will drive market expansion throughout the anticipated period.
Due to increased R&D activity in molecular biotechnology treating cholesterol and cardiovascular problems, several novel biological medications are released each year. These newer drugs will help in reducing the negative effects of existing therapies and increase patient acceptability.
The approval of new therapeutic alternatives will increase the life expectancy of individuals suffering from high cholesterol and blocked arteries. Furthermore, increased partnerships between pharmaceutical researchers and companies will support the expansion of the hyperlipidemia drug market.
Global Biobanks Market: https://www.insightslice.com/biobanks-market
Global Airway Management Devices Market: https://www.insightslice.com/airway-management-devices-market
The leading market segments of Global Hyperlipidemia Drugs Market
The hyperlipidemia market is divided primarily into statins, bile acid sequestrants, PCSK9 inhibitors, cholesterol absorption inhibitors, and other antihyperlipidemic medicines based on medication type. Statins dominated the hyperlipidemia medication market, accounting for around 30.0% of the total.
However, the statin market is expected to decrease because of the new age of hyperlipidemia drugs. The introduction of more effective medicines such as PCSK9 inhibitors and bempedoic acid, as well as a statin-resistant population, will create a shift in expected growth.
Challenges of Global Hyperlipidemia Drugs Market
The high cost of cardiovascular monitoring and diagnosis makes them inaccessible to people in underdeveloped nations. These products are presently not economical for patients from low-income families and poorer nations.
Furthermore, cardiovascular diagnostics are complex and necessitate highly experienced and skilled medical experts due to the nature of treatment. As a result, a scarcity of qualified medical personnel also limits the market expansion in this sector.
Many previously launched hyperlipidemia medications have significant serious side effects, and so regulators have employed stringent parameters for hyperlipidemia drugs. Crucial development strategies and clinical testing procedures are required before the launch of hyperlipidemia drugs onto the market. Such difficulties for pharmaceutical manufacturers will exacerbate the problems and hamper the rise of the hyperlipidemia drug market.
Proceed to purchase: https://www.insightslice.com/buy-now/1294
insightSLICE is a market intelligence and strategy consulting company. The company provides tailor-made and off the shelf market research studies. The prime focus of the company is on strategy consulting to provide end-to-end solutions. For more details, please contact our research and consulting team at firstname.lastname@example.org.
+1 707 736 6633